Head to Head Contrast: Oncotelic Therapeutics (OTCMKTS:OTLC) and Qiagen (NYSE:QGEN)

Qiagen (NYSE:QGEN) and Oncotelic Therapeutics (OTCMKTS:OTLC) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings for Qiagen and Oncotelic Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1	7	4	1	2.38
Oncotelic Therapeutics	0	0	0	0	0.00

Qiagen currently has a consensus target price of $43.15, suggesting a potential upside of 7.65%. Given Qiagen’s stronger consensus rating and higher possible upside, equities analysts plainly believe Qiagen is more favorable than Oncotelic Therapeutics.

Profitability

This table compares Qiagen and Oncotelic Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Oncotelic Therapeutics	N/A	183.45%	117.54%

Institutional & Insider Ownership

70.0% of Qiagen shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 39.2% of Oncotelic Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Qiagen has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Oncotelic Therapeutics has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500.

Earnings and Valuation

This table compares Qiagen and Oncotelic Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09 billion	3.95	$424.88 million	$1.91	20.98
Oncotelic Therapeutics	$70,000.00	266.79	$249.28 million	$0.59	0.07

Qiagen has higher revenue and earnings than Oncotelic Therapeutics. Oncotelic Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Summary

Qiagen beats Oncotelic Therapeutics on 11 of the 15 factors compared between the two stocks.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.